Literature DB >> 23599374

Proteomic identification of neoadjuvant chemotherapy-related proteins in bulky stage IB-IIA squamous cervical cancer.

Shuangwei Zou1, Qi Shen, Ying Hua, Wenxiao Jiang, Wenwen Zhang, Xueqiong Zhu.   

Abstract

OBJECTIVE: The aim of this study was to investigate the effect of neoadjuvant chemotherapy (NAC) on the human squamous cervical cancer using proteomics profiling and to obtain related proteins to NAC exposure and response.
METHODS: Paired samples of early-stage bulky squamous cervical cancer before and after NAC treatment from patients who responded to NAC were obtained and submitted to 2-dimensional gel electrophoresis and matrix-assisted laser desorption/ionization time-of-flight mass spectrometry (MS). The expression and localization of the interesting proteins in additional paired samples were confirmed by Western blot analysis and immunohistochemistry.
RESULTS: The comparison of the proteins present before and after NAC revealed that 116 protein spots were significantly changed. In all, 31 proteins were analyzed by MS, and 15 proteins were upregulated in the cancer tissue after NAC relative to the level before NAC, whereas 16 proteins were downregulated after NAC. The significantly higher expression of peroxiredoxin 1 and significantly lower expression of galectin 1 after NAC treatment were confirmed by Western blot.
CONCLUSIONS: Proteomics can be used to identify the NAC-related proteins in squamous cervical cancer. The change in proteins may be associated with NAC exposure and response, but insight into their relevance requires further study.

Entities:  

Keywords:  galectin 1; neoadjuvant chemotherapy; peroxiredoxin 1; proteomics; squamous cervical cancer

Mesh:

Substances:

Year:  2013        PMID: 23599374      PMCID: PMC3795422          DOI: 10.1177/1933719113485291

Source DB:  PubMed          Journal:  Reprod Sci        ISSN: 1933-7191            Impact factor:   3.060


  31 in total

1.  Neoadjuvant chemotherapy and radical surgery compared to radical surgery alone in bulky stage IB-IIA cervical cancer.

Authors:  N Behtash; Z Nazari; H Ayatollahi; M Modarres; F Ghaemmaghami; A Mousavi
Journal:  Eur J Surg Oncol       Date:  2006-09-06       Impact factor: 4.424

2.  Galectin 1 expression is associated with tumor invasion and metastasis in stage IB to IIA cervical cancer.

Authors:  Ha-Jeong Kim; In-Gu Do; Hye-Kyung Jeon; Young Jae Cho; Young Ae Park; Jung-Joo Choi; Chang Ohk Sung; Yoo-Young Lee; Chel Hun Choi; Tae-Joong Kim; Byoung-Gie Kim; Jeong-Won Lee; Duk-Soo Bae
Journal:  Hum Pathol       Date:  2012-08-30       Impact factor: 3.466

3.  Preliminary proteomic analysis of indomethacin's effect on tumor transplanted with colorectal cancer cell in nude mice.

Authors:  Yu-Jie Wang; Gui-Ying Zhang; Zhi-Qiang Xiao; Hong-Mei Wang; Zhu-Chu Chen
Journal:  J Biochem Mol Biol       Date:  2006-03-31

4.  Galectin-1 knockdown increases sensitivity to temozolomide in a B16F10 mouse metastatic melanoma model.

Authors:  Véronique Mathieu; Marie Le Mercier; Nancy De Neve; Sébastien Sauvage; Thierry Gras; Isabelle Roland; Florence Lefranc; Robert Kiss
Journal:  J Invest Dermatol       Date:  2007-05-10       Impact factor: 8.551

5.  Anxa2 plays a critical role in enhanced invasiveness of the multidrug resistant human breast cancer cells.

Authors:  Fei Zhang; Lin Zhang; Bin Zhang; Xiyin Wei; Yi Yang; Robert Z Qi; Guoguang Ying; Ning Zhang; Ruifang Niu
Journal:  J Proteome Res       Date:  2009-11       Impact factor: 4.466

6.  Identification of 5-fluorouracil response proteins in colorectal carcinoma cell line SW480 by two-dimensional electrophoresis and MALDI-TOF mass spectrometry.

Authors:  Cesar Sze-Chuen Wong; Vicky Wai-Ki Wong; Charles Ming-Lok Chan; Brigette Buig-Yue Ma; Edwin Pun Hui; Manson Chi-Keung Wong; Money Yan-Yee Lam; Thomas Chi-Chuen Au; Wing-Han Chan; Wah Cheuk; Anthony Tak-Cheung Chan
Journal:  Oncol Rep       Date:  2008-07       Impact factor: 3.906

7.  Up-regulation of peroxiredoxin 1 in lung cancer and its implication as a prognostic and therapeutic target.

Authors:  Joo-Heon Kim; Paul N Bogner; Sun-Hee Baek; Nithya Ramnath; Ping Liang; Hak-Ryul Kim; Chris Andrews; Young-Mee Park
Journal:  Clin Cancer Res       Date:  2008-04-15       Impact factor: 12.531

8.  Clinical efficacy of modified preoperative neoadjuvant chemotherapy in the treatment of locally advanced (stage IB2 to IIB) cervical cancer: randomized study.

Authors:  Huijun Chen; Chuan Liang; Lei Zhang; Shuang Huang; Xufeng Wu
Journal:  Gynecol Oncol       Date:  2008-07-07       Impact factor: 5.482

9.  Adenovirus-mediated transfer of siRNA against peroxiredoxin I enhances the radiosensitivity of human intestinal cancer.

Authors:  Bo Zhang; Yan Wang; Kaiyuan Liu; Xaoya Yang; Min Song; Yanyan Wang; Yun Bai
Journal:  Biochem Pharmacol       Date:  2007-09-21       Impact factor: 5.858

10.  Heat shock protein 27 protects L929 cells from cisplatin-induced apoptosis by enhancing Akt activation and abating suppression of thioredoxin reductase activity.

Authors:  Yong Zhang; Xun Shen
Journal:  Clin Cancer Res       Date:  2007-05-15       Impact factor: 12.531

View more
  6 in total

Review 1.  Molecular mechanisms of cisplatin resistance in cervical cancer.

Authors:  Haiyan Zhu; Hui Luo; Wenwen Zhang; Zhaojun Shen; Xiaoli Hu; Xueqiong Zhu
Journal:  Drug Des Devel Ther       Date:  2016-06-07       Impact factor: 4.162

2.  Predictive role of galectin-1 and integrin α5β1 in cisplatin-based neoadjuvant chemotherapy of bulky squamous cervical cancer.

Authors:  Haiyan Zhu; Aixue Chen; Saisai Li; Xuejiao Tao; Bo Sheng; Mandika Chetry; Xueqiong Zhu
Journal:  Biosci Rep       Date:  2017-09-27       Impact factor: 3.840

3.  Decreased expression of peroxiredoxin1 inhibits proliferation, invasion, and metastasis of ovarian cancer cell.

Authors:  Ming-Jun Zheng; Jing Wang; Hui-Min Wang; Ling-Ling Gao; Xiao Li; Wen-Chao Zhang; Rui Gou; Qian Guo; Xin Nie; Juan-Juan Liu; Bei Lin
Journal:  Onco Targets Ther       Date:  2018-11-02       Impact factor: 4.147

4.  PKM2 enhances chemosensitivity to cisplatin through interaction with the mTOR pathway in cervical cancer.

Authors:  Haiyan Zhu; Jun Wu; Wenwen Zhang; Hui Luo; Zhaojun Shen; Huihui Cheng; Xueqiong Zhu
Journal:  Sci Rep       Date:  2016-08-05       Impact factor: 4.379

5.  Up-regulation of peroxiredoxin-1 promotes cell proliferation and metastasis and inhibits apoptosis in cervical cancer.

Authors:  Ermei Lu; Xiaoli Hu; Chunyu Pan; Jingjing Chen; Yichi Xu; Xueqiong Zhu
Journal:  J Cancer       Date:  2020-01-01       Impact factor: 4.478

6.  Effects of Galectin-1 on Biological Behavior in Cervical Cancer.

Authors:  Mandika Chetry; Yizuo Song; Chunyu Pan; Ruyi Li; Jianan Zhang; Xueqiong Zhu
Journal:  J Cancer       Date:  2020-01-14       Impact factor: 4.207

  6 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.